G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments is antitumor activity in a melanoma model in mice

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 63-69

  Golab J ^a   Stoklosa T ^a   Zagozdzon, R ^a   Kaca, A ^a   Giermasz, A ^a   Pojda, Z ^b   Machaj, E ^c   Dabrowska, A ^a   Feleszko, W ^a   Lasek, W ^a   Iwan Osiecka, A ^a   Jakobisiak M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b WIHiE ^*  (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Granulocyte colony stimulating factor; Interleukin 12; Melanoma

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; DRUG POTENTIATION; HEMATOPOIESIS; MACROPHAGE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; INTERLEUKIN-12; LEUKOCYTE COUNT; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NITRIC OXIDE; RECOMBINANT PROTEINS; SPLEEN;

EID: 6844259872     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008266321552     Document Type: Article

References (26)

1. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
2. Stern AS, Podlaski FJ, Hulmes JD et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-12.
3. Podlaski FJ, Nanduri V, Hulmes JD et al. Molecular characterization of interleukin-12. Arch Biochem Biophys 1992; 294: 230-7.
4. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-30.
5. Brunda MJ, Gately MK. Antitumor activity of interleukin 12. Clin Immunol Immunopathol 1994; 71: 253-5.
6. Tare NS, Bowen S, Warrier RR et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995; 15: 377-83.
7. Eng VM, Car BD, Schnyder B et al. The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon γ in vivo. J Exp Med 1995; 181: 1893-8.
8. Atkins MB, Robertson MJ, Gordon M Et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-17.
9. Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 1992; 13: 77-8.
10. Gearing DP, Cosman D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the mterleukin-6 receptor. Cell 1991; 66: 9-10.
11. Hirayama F, Katayama N, Neben S et al. Synergistic interactions between interleukin-12 and steel factor in support of proliferation of murine lymphohematopoietic progenitors in culture. Blood 1994; 83: 92-8.
12. Fardoun D, Teixeira-Lebrun G, Lenormand B et al. Synergism of interleukin-12 and interleukin-3 on development of hematopoietic progenitors. Eur J Haematol 1995; 9: 1-4.
13. Lasek W, Feleszko W, Gola(Combining ogonek)b J et al. Antitumor effects of the combination immunotherapy with IL-12 and TNF-α in mice. Cancer Immunol Immunother 1997 (accepted for publication).
14. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153: 1697-1706.
15. Yu W-G, Yamamoto N,Takenaka H et al. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996; 8: 655-65.
16. Welte K, Gabrilove J, Bromchud MH et al. Filgrastim (r-metHuGCSF): The first 10 years. Blood 1996; 88: 1907-29.
17. Segawa K, Ueno Y, Kataoka T. In vivo tumor growth enhancement by granulocyte colony-stimulating factor. Jpn J Cancer Res 1991; 82: 440-7.
18. Colombo MP, Ferrari G, Stoppacciaro A et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889-97.
19. Stoppacciaro A, Melani C, Parenza M et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J Exp Med 1993; 178: 151-61.
20. Wiltschke C, Krainer M, Wagner A et al. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp Hematol 1995; 23: 402-6.
21. Perussia B, Kobayashi M, Rossi ME et al. Immune Interferon enhances functional properties of human granulocytes: Role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte colony-stimulating factor. J Immunol 1987; 138: 765-74.
22. Hill HR, Augustine NH, Jaffe HS. Human recombinant interferon γ enhances neonatal polymorphonuclear leukocyte activation and movement, and increases free intracellular calcium. J Exp Med 1991; 173: 767-70.
23. Caspar CB, Seger RA, Burger J et al. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-71.
24. Katoh M, Takada M, Nakayama M et al. Potentiation of neutrophil functions with administration of granulocyte colony-stimulating factor to donors for granulocyte transfusions. Blood 1996; 87: 3524-5.
25. Roilides E, Uhlig K, Venzon D et al. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma Interferon. Infect Immun 1993; 61: 1185-93.
26. Bociek GB, Armitage JO. Hematopoietic growth factors. CA-A Cancer J Clin 1996; 46: 165-84.